Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom

Seizure

Volumn 19, Issue 1, 2010, Pages 1-11

  Verdian, Lara ^a   Yi, Yunni ^b  

^a EISAI CO LTD   (Japan)

^b MAPI VALUES   (United States)

Author keywords

Cost effectiveness; Drop attack; Lennox Gastaut Syndrome; Quality adjusted life years; Rufinamide

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; RUFINAMIDE; TOPIRAMATE; VALPROIC ACID;

ARTICLE; ATONIC SEIZURE; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HEALTH STATUS; HUMAN; LENNOX GASTAUT SYNDROME; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; TONIC SEIZURE; TREATMENT RESPONSE; UNITED KINGDOM;

ANTICONVULSANTS; CHILD; CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; DRUG UTILIZATION; EPILEPSY; FOLLOW-UP STUDIES; FRUCTOSE; GREAT BRITAIN; HEALTH STATUS; HUMANS; MARKOV CHAINS; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; TRIAZINES; TRIAZOLES;

EID: 73749083670     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2009.10.003     Document Type: Article

References (64)

1. Aicardi J. Epileptic encephalopathies of early childhood. Curr Opin Neurol Neurosurg 5 (1992) 344-348
2. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., and Perucca E. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res 34 (1999) 1-41
3. Fitzgerald L.F., Stone J.L., Hughes J.R., Melyn M.A., and Lansky L.L. The Lennox-Gastaut Syndrome: electroencephalographic characteristics, clinical correlates, and follow-up studies. Clin Electroencephalogr 23 (1992) 180-189
4. Trevathan E., Murphy C.C., and Yeargin-Allsopp M. Prevalence and descriptive epidemiology of Lennox-Gastaut Syndrome among Atlanta children. Epilepsia 38 (1997) 1283-1288
5. Rantala H., and Putkonen T. Occurrence, outcome, and prognostic factors of infantile spasms and Lennox-Gastaut Syndrome. Epilepsia 40 (1999) 286-289
6. European Medicines Agency. European Medicines Agency-public summary of positive opinion for orphan designation of rufinamide for the treatment of Lennox-Gastaut syndrome (2007). http://www.emea.europa.eu/pdfs/human/comp/opinion/12230704en.pdf http://www.emea.europa.eu/pdfs/human/comp/opinion/12230704en.pdf
7. US Food and Drug Administration. US Food and Drug Administration-list of orphan products designation (2008). http://www.fda.gov/orphan/designat/list.xls www.fda.gov/orphan/designat/list.xls
8. Camfield P., and Camfield C. Epileptic syndromes in childhood: clinical features, outcomes, and treatment. Epilepsia 43 Suppl. 3 (2002) 27-32
9. Begley C.E., Famulari M., Annegers J.F., Lairson D.R., Reynolds T.F., Coan S., et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 41 (2000) 342-351
10. Roger J., Dravet C., and Bureau M. The Lennox-Gastaut syndrome. Cleve Clin J Med 56 Suppl. (Pt 2) (1989) S172-S180
11. Panayiotopoulos C. Epileptic encephalopathies in infancy and early childhood. A clinical guide to epileptic syndromes and their treatment. 2nd ed. (2007), Springer 223-266
12. Hancock E., and Cross H. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev (2003)
13. Arzimanoglou A., French J., Blume W.T., Cross J.H., Ernst J.P., Feucht M., et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol 8 (2009) 82-93
14. French J.A. The role of new antiepileptic drugs. Am J Manage Care 7 Suppl. (2001) S209-S214
15. Glauser T.A., Kluger G., Sachdeo R., Krauss G., Perdomo C., and Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 70 (2008) 1950-1958
16. Wheless J.W., Clarke D.F., Arzimanoglou A., and Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord 9 (2007) 353-412
17. Motte J., Trevathan E., Arvidsson J.F.V., Barrera M.N., and Mullens E.L. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med 337 (1997) 1807-1812
18. Sachdeo R.C., Glauser T.A., Ritter F., Reife R., Lim P., Pledger G., et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 52 (1999) 1882-1887
19. Dodson W.E. Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia 34 Suppl. 7 (1993) S18-S24
20. Arroyo S., and de la Morena A. Life-threatening adverse events of antiepileptic drugs. Epilepsy Res 47 (2001) 155-174
21. French J., Smith M., Faught E., and Brown L. Practice advisory: the use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 52 (1999) 1540-1545
22. Thompson P.J., Baxendale S.A., Duncan J.S., and Sander J.W. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 69 (2000) 636-641
23. Arroyo S., Dodson W.E., Privitera M.D., Glauser T.A., Naritoku D.K., Dlugos D.J., et al. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand 112 (2005) 214-222
24. Zaccara G., Gangemi P.F., and Cincotta M. Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure 17 (2008) 405-421
25. McElroy S.L., Hudson J.I., Capece J.A., Beyers K., Fisher A.C., and Rosenthal N.R. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry 61 (2007) 1039-1048
26. Cheng-Hakimian A., Anderson G.D., and Miller J.W. Rufinamide: pharmacology, clinical trials, and role in clinical practice. Int J Clin Pract 60 (2006) 1497-1501
27. Aldenkamp A.P.J., and Alpherts W.C. The effect of the new antiepileptic drug rufinamide on cognitive functions. Epilepsia 47 (2006) 1153-1159
28. Rawlins M.D., and Culyer A.J. National Institute for Clinical Excellence and its value judgments. BMJ 329 (2004) 224-227
29. Drummond M.F., Wilson D.A., Kanavos P., Ubel P., and Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 23 (2007) 36-42
30. Briggs A., and Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 13 (1998) 397-409
31. Verdian L., Yi Y., Oyee J., Heyes A., and Tolley K. Eliciting preferences for health states associated with Lennox-Gastaut syndrome (LGS). Poster 1. 352 presented at the 62nd meeting of the American Epilepsy Society (2008)
32. European Medicines Agency. European Medicines Agency-guideline on clinical investigation of medicinal products in the treatment of epileptic disorders (2009). http://www.emea.europa.eu/pdfs/human/ewp/056698endraft.pdf http://www.emea.europa.eu/pdfs/human/ewp/056698endraft.pdf
33. Briggs A., Claxton C., and Sculpher M. Key stages of developing a decision model. Decision modelling for health economic evaluation (2006), Oxforn University Press
34. Yagi K. Evolution of Lennox-Gastaut syndrome: a long-term longitudinal study. Epilepsia 37 Suppl. 3 (1996) 48-51
35. Beaumanoir A., and Blume W. The Lennox-Gastaut syndrome. In: Roger J., Bureau M., Dravet C., Genton P., Tassinari C.A., and Wolf P. (Eds). Epileptic syndromes in infancy, childhood and adolescence. 4th ed. (2005), John Libbey Eurotext, Paris 125-148
36. Gartlehner G., and Moore C.G. Direct versus indirect comparisons: a summary of the evidence. Int J Technol Assess Health Care 24 (2008) 170-177
37. National Institute for Health and Clinical Excellence. National Institute for Health and Clinical Excellence-Updated guide to the methods of technology appraisal (2008). http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf
38. Glenny A.M., Altman D.G., Song F., Sakarovitch C., Deeks J.J., D'Amico R., et al. Indirect comparisons of competing interventions. Health Technol Assess 9 (2005) 1-iv
39. Song F., Altman D.G., Glenny A.M., and Deeks J.J. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 326 (2003) 472
40. Jansen J.P., Crawford B., Bergman G., and Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 11 5 (2008) 956-964
41. Brazier J., Deverill M., Green C., Harper R., and Booth A. A review of the use of health status measures in economic evaluation. Health Technol Assess 3 (1999) i-164
42. British National Formulary. British National Formulary (2007), BMJ Publishing Group Ltd./RPS Publishing
43. Personal Social Services Research Unit. Personal Social Services Research Unit-unit costs of health and social care (2007). http://www.pssru.ac.uk/uc/uc2007contents.htm http://www.pssru.ac.uk/uc/uc2007contents.htm
44. Department of health. Department of Health-NHS reference costs 2006-07 (2008). http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082571 http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082571
45. Fenwick E., Claxton K., and Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 10 (2001) 779-787
46. Dulac O., and Engel J. Lennox-Gastaut syndrome (2005). http://www.ilae-epilepsy.org/Visitors/Centre/ctf/lennox_gastaut.cfm http://www.ilae-epilepsy.org/Visitors/Centre/ctf/lennox_gastaut.cfm
47. Frew E.J., Sandercock J., Whitehouse W.P., and Bryan S. The cost-effectiveness of newer drugs as add-on therapy for children with focal epilepsies. Seizure 16 (2007) 99-112
48. Benedict A, Verdian L, Maclaine G. The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the United Kingdom. Phamacoeconomics; in press.
49. Majoie H.J., Berfelo M.W., Aldenkamp A.P., Evers S.M., Kessels A.G., and Renier W.O. Vagus nerve stimulation in children with therapy-resistant epilepsy diagnosed as Lennox-Gastaut syndrome: clinical results, neuropsychological effects, and cost-effectiveness. J Clin Neurophysiol 18 (2001) 419-428
50. Wilby J., Kainth A., Hawkins N., Epstein D., McIntosh H., McDaid C., et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess 9 (2005) 1-iv
51. Maltoni S., and Messori A. Lifetime cost-utility analysis of patients with refractory epilepsy treated with adjunctive topiramate therapy: cost-effectiveness in refractory epilepsy. Clin Drug Invest 23 (2003) 225-232
52. Messori A., Trippoli S., Becagli P., Cincotta M., Labbate M.G., and Zaccara G. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. Eur J Clin Pharmacol 53 (1998) 421-427
53. Vera-Llonch M., Brandenburg N.A., and Oster G. Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy. Epilepsia 49 (2008) 431-437
54. Spackman D.E., Yeates A., Rentz A.M., and Hutton J. The cost effectiveness of zonisamide as adjunctive therapy in adult partial seizure epilepsy. J Med Econ F (2007)
55. Begley C.E., Annegers J.F., Lairson D.R., Reynolds T.F., and Hauser W.A. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 35 (1994) 1230-1243
56. Matsuo F., Bergen D., Faught E., Messenheimer J.A., Dren A.T., Rudd G.D., et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0. 5 Clinical Trial Group. Neurology 43 (1993) 2284-2291
57. Guberman A., Neto W., and Gassmann-Mayer C. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol Scand 106 (2002) 183-189
58. Eisai data on file. Study 022-multicenter, randomized, double-blind, placebo-controlled, parallel trial comparing the safety and efficacy of rufinamide as adjunctive therapy relative to placebo in patients with inadequately controlled Lennox-Gastaut syndrome (2008)
59. Bombardier C., and Maetzel A. Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies?. Ann Rheum Dis 58 Suppl. 1 (1999) I82-I85
60. Kluger G., Kurlemann G., Haberlandt E., Ernst J.P., Runge U., Schneider F., et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav 14 3 (2009) 491-495
61. Topiramate summary of product characteristics (2008). http://emc.medicines.org.uk/document.aspx%3FdocumentId=6768 http://emc.medicines.org.uk/document.aspx?documentId=6768
62. Lamotrigine summary of product characteristics (2007). http://emc.medicines.org.uk/medicine/4228/SPC/Lamictal+Combined+Tablets/ http://emc.medicines.org.uk/medicine/4228/SPC/Lamictal+Combined+Tablets/
63. Langtry H.D., and Wagstaff A.J. Management of epilepsy: defining the role of lamotrigine. Dis Manage Health Out 1 (1997) 254-270
64. GMB-Briton's General Union. GMB Briton's General Union-average hourly pay in 81 out of 204 UK areas below 90% of UK average of £12.50 per hour (2005). http://www.gmb.org.uk/Templates/PressItems.asp%3FPrintFriendly=True%26NodeID=93132 http://www.gmb.org.uk/Templates/PressItems.asp?PrintFriendly=True&NodeID=93132